Lirui Yang1, Huimin Zhang1, Menggengtuya Cai2, Yubao Zou1, Xiongjing Jiang1, Lei Song1, Erpeng Liang1, Jin Bian1, Haiying Wu1, Rutai Hui1. 1. a Hypertension Division , State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China. 2. b Chronic Disease Department , Centers for Disease Control , Hebukesaier County , Xinjiang Uygur Autonomous Region , China.
Abstract
OBJECTIVE: To examine whether spironolactone could reduce the severity of obstructive sleep apnea (OSA) and lower blood pressure in patients with resistant hypertension. METHODS: This was a blank-controlled, single-center study. Patients with resistant hypertension and moderate-to-severe OSA (apnea-hypopnea index >15 events/h) were enrolled and randomly assigned to the therapy or control group. Patients in the therapy group were administered spironolactone 20 mg once daily (up to 40 mg once daily for 4 weeks, if required) in addition to original antihypertensive medication. Follow-up was 12 weeks. RESULTS:Thirty patients were enrolled (n = 15 per group). After 12 weeks of follow-up, apnea-hypopnea index (21.8 ± 15.7 vs. 1.8 ± 12.8, p < 0.05), hypopnea index (9.8 ± 11.1 vs. -2.7 ± 16.8, p < 0.05), oxygen desaturation index (20.8 ± 15.0 vs. 0.3 ± 16.1, p < 0.05), clinical blood pressure, ambulatory blood pressure, and plasma aldosterone level (9.8 ± 6.3 vs. 2.9 ± 6.7, p < 0.05) were reduced significantly in the therapy group compared with the control group. No side effects were reported. CONCLUSIONS:Spironolactone reduced the severity of OSA and reduced blood pressure in resistant hypertension patients with moderate-to-severe OSA. These findings may assist in the treatment of OSA in patients with resistant hypertension.
RCT Entities:
OBJECTIVE: To examine whether spironolactone could reduce the severity of obstructive sleep apnea (OSA) and lower blood pressure in patients with resistant hypertension. METHODS: This was a blank-controlled, single-center study. Patients with resistant hypertension and moderate-to-severe OSA (apnea-hypopnea index >15 events/h) were enrolled and randomly assigned to the therapy or control group. Patients in the therapy group were administered spironolactone 20 mg once daily (up to 40 mg once daily for 4 weeks, if required) in addition to original antihypertensive medication. Follow-up was 12 weeks. RESULTS: Thirty patients were enrolled (n = 15 per group). After 12 weeks of follow-up, apnea-hypopnea index (21.8 ± 15.7 vs. 1.8 ± 12.8, p < 0.05), hypopnea index (9.8 ± 11.1 vs. -2.7 ± 16.8, p < 0.05), oxygen desaturation index (20.8 ± 15.0 vs. 0.3 ± 16.1, p < 0.05), clinical blood pressure, ambulatory blood pressure, and plasma aldosterone level (9.8 ± 6.3 vs. 2.9 ± 6.7, p < 0.05) were reduced significantly in the therapy group compared with the control group. No side effects were reported. CONCLUSIONS:Spironolactone reduced the severity of OSA and reduced blood pressure in resistant hypertensionpatients with moderate-to-severe OSA. These findings may assist in the treatment of OSA in patients with resistant hypertension.
Authors: Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: Piotr Dobrowolski; Sylwia Kołodziejczyk-Kruk; Ewa Warchoł-Celińska; Marek Kabat; Urszula Ambroziak; Aleksandra Wróbel; Piotr Piekarczyk; Aleksandra Ostrowska; Magdalena Januszewicz; Paweł Śliwiński; Jacques W M Lenders; Andrzej Januszewicz; Aleksander Prejbisz Journal: J Clin Sleep Med Date: 2021-04-01 Impact factor: 4.062
Authors: Peter Makai; Joanna IntHout; Jaap Deinum; Kevin Jenniskens; Gert Jan van der Wilt Journal: J Gen Intern Med Date: 2017-03-08 Impact factor: 5.128